US equities |
MU $994.01 ▼-3.40% NVDA $226.17 ▼-1.36% SNDK $1,484.66 ▼-6.14% META $746.26 ▲+3.84% SPCX $163.74 ▲+0.72% AMD $591.39 ▼-2.75% MSFT $539.76 ▲+0.88% TSLA $378.74 ▼-1.03%
FinancialContent

GH Research PLC - Ordinary Shares (NQ:GHRS)

20.35 -0.76 (-3.60%)
Delayed Quote Updated: 12:52 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
GH Research Announces Publication of Phase 2a Postpartum Depression Results
From GH Research PLC
Via GlobeNewswire
News headline image
These Analysts Revise Their Forecasts On GH Research After Q1 Results ↗
GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program. 
Via Benzinga
News headline image
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Pricing of $117.5 Million Underwritten Offering
From GH Research PLC
Via GlobeNewswire
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
From GH Research PLC
Via GlobeNewswire
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
From GH Research PLC
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Why Is GHRS Stock Rising Today? ↗
GH Research stated that the FDA has cleared GH001 for a clinical investigation in the U.S. 
Via Stocktwits
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
GH Research to Announce IND Status for GH001
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research PLC (NASDAQ:GHRS) Reports Q3 2025 Earnings Beat and Clinical Progress ↗
GH Research Q3 2025 results show a slight EPS beat. The biotech firm is focused on resolving the FDA clinical hold for its GH001 treatment for depression. 
Via Chartmill
Topics Earnings
News headline image
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
Depression-Focused GH Research Shares Could See Significant Upside: Analyst ↗
GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential. 
Via Benzinga
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
GH Research Announces Global Pivotal Program Plans and Further Development Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
From GH Research PLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >